Jacobio Pharmaceuticals

2021 Annual Results



以患者受益为导向
利用最新的科研成果研发全球首创新药

Focus on a patient-centric approach
Develop transformative medicine through scientific breakthroughs
and innovative technology

Our Strategy

In-house R&D

Focus on in-house R&D leveraging our allosteric inhibitor tech platform rather than in-licensing

Global FIC

Aim for "first-in-class" drugs over me-too drugs

Global Market

Explore MNC partnership to capture global market

Full Function Pharma

Expand areas of manufacturing and commercialization in China

Our Progression

Founded in 2015
Set the goal of global innovation

2015

HKEX listing

2020

AbbVie Partnership
regarding SHP2

Clinical Milestones

JAB-3312 (SHP2i)
- Mono – Dose expansion initiated
- Globally initiated 4 combos
  - combo w/PD-1 (Pembrolizumab)
  - combo w/MEKi (Binimetinib)
  - combo w/KRAS G12Ci
    - *Sotorasib, Global*
    - *JAB-21822, China*
  - combo w/EGFRi (Osimertinib)

JAB-21822 (KRAS G12Ci)
- RP2D determined
- Pivotal trial to be initiated in 2022 2H (NSCLC)
- NSCLC
  - mono 2/3L,
  - mono STK-11 co-mutant 1L,
  - combo w/PD-1

  CRC (combo w/EGFR mAb)

JAB-3068 (SHP2i)
- China PhIIa mono trial enrollment completed
- combo w/ PD-1 (JS001) in China

JAB-8263 (BETi)
- Dose escalation ongoing
- Solid tumor and hematological malignancy in US ad China

New INDs

- JAB-21822 (KRAS G12Ci)
- JAB-2485 (Aurora Ai)
- JAB-BX102 (CD73 antibody)
- JAB-6343 (FGFR4i)

2021-2022 March

JAB-21822 NDA

Commercial Manufacturing
First Product Launch

2023-2024

Our Team

Yinxiang Wang Ph.D.
Chief Executive Officer
Chairman of our Board

- Chairman and CEO
- Former Board Director and CEO of Betta Pharma
- Chairman on the New Drug R&D Committee of China for PhIRDA (2017-2019)
- Vice Chairman on the Anti-tumor Drug Professional Committee of Chinese Pharmaceutical Association
- Over 20 years of experience in the industry

Xiaojie Wang, EMBA
President of Administration

Yunyan Hu, M.S.
Senior Vice President

Andrea Wang-Gillam M.D, Ph.D.
CMO and Senior Vice President

Haijun Wang, Ph.D.
Senior Vice President of Data and Information Management

Wayne Long, Ph.D.
Vice President of Chemistry

Yuli Ding, M.S.
Vice President of Clinical Development

Bin Fan, Ph.D.
Vice President of Clinical Pharmacology

Qiao Li, Ph.D.
Vice President of Biostatistics and Data Science

Yanping Wang, M.S.
Vice President of Pharmacology

Hong Cao, M.S.
Vice President of CMC

Jian Kang , M.D
Vice President of Intellectual Property

Tiffany Yang, M.S.
Vice President of Human Resources

Our Allosteric Inhibitor Technology Platform



We have validated our discovery and validation platform and gained competitive advantages.

Advance Novel Drug Development in Key Oncogenic Pathways

RAS

The beating heart of cancer



MYC

The master regulator



I/O pathways

The Defensive barrier

RB pathway

The brake pads of cancer

Tumor Metabolic Pathways

The suppliers of cancer

p53

The guardian of the genome

The “BIG 6” pathways cover 70%-80% cancer.

1. Nusse R, Clevers H. Cell 2017;169(6):985–99;
2. Lane DP. Nature 1992;358(6381):15–6;
3. Waters AM, Der CJ. Cold Spring Harb Perspect Med 2018;8(9):a031435;
4. Dang CV, et al. Cell 2012;149(1):22–35.

Deep Dive in RAS Pathway to Address Unmet Need



JAB-BX300 (mAb)

JAB-21822
KRAS G12C inhibitor

JAB-3312
JAB-3068
SHP2 inhibitor

JAB-23400
KRAS^{multi} inhibitor

JAB-22000
KRAS G12D inhibitor

JAB-23000
KRAS G12V inhibitor

JAB-2485
Aurora A inhibitor

Clinical Stage

Pre-clinical

Our SHP2 Inhibitor JAB-3312 as a Potential Best-in-Class Drug

TOP3 SHP2 inhibitor

(in order of US FDA IND filing date)

Company Name	Company	US FDA IND
TNO-155	Novartis	May 2017 (US)
JAB-3068 JAB-3312	Jacobio/ AbbVie	Dec 2017 (US)
RMC-4630	Revolution Medicines/Sanofi	Sep 2018 (US)

SHP2 Functions in the Downstream of anti-PD-1 and Upstream of KRAS with Tremendous Market

New cases estimated worldwide with RAS/MAPK pathway alterations

5.5 million (worldwide)

New cases estimated worldwide per annum

90+% with limited/no treatment options

BRAF class III/ NF1 LOF mutant solid tumors

SHP2 mono strategies

KRASi / EGFRi MEKi combo

SHP2 combo strategies

Market potential and clinical efficacy of SHP2 in the PD-(L)1 pathway

<30%

ORR of PD-(L)1 monotherapy in most cancer types

3.37 million pts (worldwide in 2019)

Number of patients with the 5 largest cancer types who did not respond to PD-(L)1

PD-(L)1 combo

SHP2 combo strategies

Our SHP2 Inhibitor JAB-3312 as a Potential Best-in-Class Drug

Preclinical comparison

	JAB-3312	RMC-4550 In-house or ref
SHP2 biochemical IC_{50} (nM)	1.5	10.4
Binding kinetics KD (nM)	0.206	13.6
Cellular p-ERK IC_{50} in NCI-H358 (nM)	3.64	28 (ref)
Cellular p-ERK IC_{50} in KYSE-520 (nM)	0.32	9.1 (ref)
Cellular proliferation KYSE-520 IC_{50} (nM)	3.5	127



Clinical dose

JAB-3312
1-8mg QD

JAB-3068
50-300 mg QD

TNO-155
20-70 (or higher) mg QD 21/7

RMC-4630
20-80 mg QD
200mg D1/D2 weekly

SHP2 Inhibitor-Global Development Plan

Given the unique dual-blockade mechanism of SHP2 against RAS pathway and PD-(L)1 pathway, we plan to develop our SHP2 inhibitors as monotherapy and as a backbone for various combination therapies

Asset	Regimen	Indications	Phase I	Phase IIa	Recent development
JAB-3312 SHP2 abbvie	Mono	Solid tumors	*US trial*		
	Mono	Solid tumors	*China trial*		Phase IIa initiated with FPI in Jan 2022
	Mono	BRAF class 3/ NF1 LOF mutant solid tumors	*US trial*		Phase IIa initiated with FPI in Dec 2021
	Combo w/PD-1 mAb	NSCLC, HNSCC, ESCC	*Global trial*		Phase IIa Initiated in Feb 2022
	Combo w/EGFRi	Osimertinib resistant NSCLC	*Global trial*		FPI in Jan 2022
	Combo w/KRAS G12Ci	KRAS G12C mut NSCLC	*Global trial*		FPI in Jan 2022
	Combo w/MEKi	KRAS mut CRC/ Pancreatic cancer	*Global trial*		
JAB-3068 SHP2 abbvie	Mono	Solid tumors	*US trial*		
	Mono	ESCC, HNSCC, NSCLC	*China trial*		
	Combo w/PD-1 mAb	ESCC, HNSCC, NSCLC	*China trial*		

CRC = colorectal cancer; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small cell lung cancer

[1] We assume the data of Phase IIb registrational trial will be used for NDA submissions of JAB-3068 and JAB-3312 in China and the U.S.

Our Diversified KRAS Inhibitor Portfolio

KRAS Prevalence In Tumors With High Unmet Need [1-3]

NSCLC



KRAS ^{mt} total ~ 25%

KRAS G12C	~ 14%
KRAS G12D	~ 4%
KRAS G12V	~ 6%

CRC



KRAS ^{mt} total ~ 35%

KRAS G12C	~ 3-4%
KRAS G12D	~ 12%
KRAS G12V	~ 8%

Pancreatic Cancer



KRAS ^{mt} total ~ 90%

KRAS G12C	~ 2%
KRAS G12D	~ 36%
KRAS G12V	~ 27%

KRAS G12C | KRAS G12D | KRAS G12V | Other KRAS ^{mut} | WT KRAS



JAB-21822 KRAS G12Ci

Currently in Phase IIa
Pivotal trial to be initiated in China in 2022 H2



JAB-23400 KRAS^{multi} inhibitor

Candidate nominated in Feb 2022
Target to submit IND in 2023



JAB-22000 KRAS G12Di

Lead optimization stage
Target to submit IND in 2023



JAB-23000 KRAS G12Vi

Hit-to-lead stage
Target to submit IND during 2023 to 2024

1. ZehirA, et al. Nat Med. 2017;23(6)703-713.
2. 2. KrakstadC, et al. PLoSOne. 2012;7(12):e52795.
3. 3. NIH TCGA: The Cancer Genome Atlas. February 11, 2021. https://www.cbioportal.org.

KRAS G12Ci JAB-21822-Global Development Plan

Accelerate the clinical development of JAB-21822 utilizing strong internal capacities and extensive external resources

- Achieved FPI in China within 2 months after IND approval
- Monotherapy and combination therapies are being rapidly advanced in clinical setting, sustaining competitive advantage.

Asset	Regimen	Indications	IND	Phase I	Phase IIa	Recent development	Upcoming Milestone (expected)
JAB-21822 KRAS G12C	Mono	NSCLC, CRC	*Global trial*			FPI in Sep 2021	
	Mono	NSCLC, CRC	*China trial*			Dose expansion initiated with FPI in Mar 2022	Pivot trial to be initiated in 2022 2H
	Mono	NSCLC with STK-11 co-mutation	*Global trial*			IND approved In Oct 2021	FPI (2022 2H)
	Combo w/PD-1 mAb	NSCLC	*China trial*			IND approved in Oct 2021	
	Combo w/SHP2i	NSCLC	*China trial*			IND approved in Feb 2022	FPI (2022 Q2)
	Combo w/EGFR mAb	CRC	*China trial*			FPI in Feb 2022	

Preliminary Clinical Results

- RP2D determined
- Impressive preliminary efficacy
- Safe and well tolerated

Exploring potential global partnering deal while Jacobio retains the greater China right

CRC = colorectal cancer; NSCLC = non-small cell lung cancer; 2H=Second Half, Q2 = Second Quarter

Synergistic Combinatorial Strategy among In-house Assets

RAS

JAB-3312/3068
JAB-21822
JAB-23400
JAB-22000
JAB-23000
JAB-BX300



MYC

JAB-8263
JAB-2485



I/O pathways

JAB-3312/3068
JAB-BX102
JAB-BX300
JAB-26000



RB pathway

JAB-2485



Tumor Metabolic Pathways

JAB-24000

P53

JAB-30000

1. Nusse R, Clevers H. Cell 2017;169(6):985–99;
2. Lane DP. Nature 1992;358(6381):15–6;
3. Waters AM, Der CJ. Cold Spring Harb Perspect Med 2018;8(9):a031435;
4. Dang CV, et al. Cell 2012;149(1):22–35.

Our Diverse Pipeline Targeting Critical Pathways

Asset	Target & pathway	Indications	Combo Strategy	Pre-clinical	Phase I	Phase IIa
JAB-3312/ JAB-3068	SHP2 (RAS pathway, I/O)	Solid tumors, including NSCLC, HNSCC, ESCC	**KRASi**, PD-1, EGFRi	*US, China*		
JAB-21822	KRAS G12C (RAS pathway)	NSCLC, CRC	**SHP2i**, PD-1, EGFR mAb	*US, China, Europe*		
JAB-8263	BET (MYC pathway)	Solid tumors Blood tumors	**Aurora Ai**, JAKi, PD-1	*US, China*		
JAB-2485	Aurora A (RB pathway)	Solid tumors	**BETi**, **SHP2i**, **KRASi**	*US*		
JAB-BX102	CD73 mAb (I/O)	Solid tumors	PD-1	*US, China*		
JAB-24114	Undisclosed (Tumor metabolic pathway)	NSCLC, HNSCC	**KRASi**, **P53i**, **BETi**, PD-1			
JAB-BX300	Undisclosed (RAS pathway)	PDAC, CRC	**SHP2i**, **KRASi**			
JAB-26766	Undisclosed (I/O)	SCLC, HNSCC, ESCC	**SHP2i**, PD-1			
JAB-23400	$KRAS^{MULTI}$ (RAS pathway)	PDAC, CRC, NSCLC	**SHP2i**, SOS1i, **Aurora Ai**			
JAB-22000	KRAS G12D (RAS pathway)	PDAC, CRC, NSCLC	**SHP2i**, SOS1i, **Aurora Ai**			
JAB-23000	KRAS G12V (RAS pathway)	PDAC, CRC, NSCLC	**SHP2i**, SOS1i, **Aurora Ai**			
JAB-30000	P53 (P53 pathway)	Solid tumors	**KRASi**, **JAB-24114**, PD-1			

FIC/FIC potential

BIC potential

Potent BET Inhibitor JAB-8263

Asset	Regimen	Indications	IND	Phase I	Recent development	Upcoming Milestone (expected)
JAB-8263 BET	Mono	Solid tumors	*US trial*			RP2D to be determined in 2022 2H
	Mono	Solid tumors	***China trial***		FPI in Feb 2022	
	Mono Combo w/JAKi	MF and AML	***China trial***		FPI in Apr 2021	

Strong Antitumor Effect



- Highly effective in solid and hematologic cancer models
- Greater anti-tumor response at lower dose

JAB-8263(0.15 mg/kg) TGI=80% BMS-986158(1.5 mg/kg) TGI=71%

Preliminary Clinical Results

- Early signals of clinical benefit
- Wide safety window
- Favorable PK profile

Market Potential

To date, there has been no approved and marketed BET inhibitors globally.

Indications:
Solid Tumor
NMC, NSCLC, SCLC, CRPC, ESCC, Ovarian Cancer (4.7 million by 2030)
Hematologic Tumors
MF (127,500 by 2030) AML (187,600 by 2030)

Highly Selective Aurora A Inhibitor JAB-2485

Asset	Regimen	Indications	IND	Phase I	Recent development	Upcoming Milestone (expected)
JAB-2485 Aurora A	Mono	Solid tumors	*US trial*		IND approved in Jan 2022	FPI (2022 2H)

- **No** Aurora A kinase inhibitor had been **approved and marketed** globally.
- **JAB-2485** is one of top 3 highly selective Aurora A inhibitors in clinical stage

Strong Anti-tumor Effect in Xenografts



- Greater anti-tumor response at lower dose

JAB-2485 (5 mg/kg) TGI=79% LY329566 (20 mg/kg) TGI=79%

Combinational Anti-tumor Effect



- Significant synergistic effect when combining with chemotherapy.

- **More specificity:**
  ~2000-fold selectivity over Aurora B in biochemical and cell-based assay

- **Indications**
  Small cell lung cancer (330,000 new cases in 2020)

  Triple negative breast cancer (339,000 new cases in 2020)

Highly Differentiated Anti-CD73 Antibody JAB-BX102

Clinical Plan

Asset	Regimen	Indications	IND	Phase I	Recent development	Upcoming Milestone (expected)
JAB-BX102 CD73 mAb (I/O)	Mono Combo w/PD-1 mAb	Solid tumors	*US trial*		IND approved in Oct 2021	FPI (2022 1H)
	Mono	Solid tumors	*China trial*		IND submitted in Jan 2022	

Excellent Efficacy & Safety

- Direct inhibition of CD73 enzyme activity – better efficacy



- Efficiently elimate CD73 from the cell surface by inducing internalization of surface CD73



- ✓ Recognize the N-terminal epitope of CD73
- ✓ In vivo PK/PD model, complete CD73 inhibition **without the "hook effect"**

Key Pipeline Assets with First-in-Class Potential

Global TOP3 Potential

Clinical Stage

JAB-3068/3312

- SHP2 inhibitor
- 2nd FDA IND
- Clinical - Phase IIa

JAB-2485

- Aurora A inhibitor
- 2nd FDA IND
- Clinical - Phase I

2022 IND

JAB-24114

- Tumor metabolic Pathway
- One Program in Ph I
- 2022 IND

JAB-26766

- I/O
- One Program in Ph I
- 2022 IND

JAB-BX300 (mAb)

- RAS pathway
- One Program in Ph I
- 2022 IND

2023-2024 IND

JAB-23400

- $KRAS^{multi}$ inhibitor
- No IND Globally
- 2023 IND

JAB-22000

- KRAS G12D inhibitor
- No IND Globally
- 2023 IND

JAB-30000

- P53 inhibitor
- No IND Globally
- 2023-2024 IND

JAB-23000

- KRAS G12V inhibitor
- No IND Globally
- 2023-2024 IND

Expanding Our Pipeline to Off-the-shelf Cell Therapies

Strategic Layout in Cell Therapy



- Collaborate with Hebecell to develop the **next-generation** iPSC-NK cell therapy
- Key transaction terms:
  - $25M of consideration in total
  - 19.74% of the share capital (fully-diluted)
  - Dr. Wang Yinxiang was appointed as Chairman of Hebecell
- **Boston R&D Center** - around 30 employees

  Beijing R&D Center - established in Q4 2021
- **Expected IND – 2023**
- Enhance our capability to **explore clinical value** of **combination** therapies between our current programs and off-the-shelf cell therapies

iPSC Derived-NK -- Hebecell Platform

3D Culture Without Feeder Cells

NK 1.0

Donor Derived

NK 2.0

iPSC Derived 2D Culture Feeder Cells

Fate THERAPEUTICS
CENTURY
Cytovia
editas
astellas

NK 3.0

iPSC Derived 3D Bioreactor Without Feeder Cells

HebeCell

3D Bioreactor

Cost-effective
industrial scalability

iPSC-NK Is Changing the Game in Cell Therapy

Universal, Off-the-Shelf Cell Products Derived from Renewable Master Cell Lines

	Autologous CAR -T	iPSC Derived NK
Safety		
Graft Versus Host Disease Risk(GvHD)	Low	Low
Cytokine Release Syndrome (CRS) or NeurotoxicityRisk	High	Low
Manufacturing		
Off-the-shelf Product	-	++
Cost of Manufacturing	+++++	+
Ease of Gene Editing	++	+++++
Master Cell Bank	-	+++
Homogeneous Product	+	+++
Batch to Batch Variation	Yes	No
Multiple Dosing	No	Yes
Efficacy		
Persistence	+++++	++
CAR-Independent Tumor Cytotoxicity	-	+

Advantages of iPSC-NK

- Off-the-shelf Availability
- Uniform Product
- Patient Accessibility
- Multiplexed Engineering
- Lower GvHD/CRS risk

On Target to Capture the Global Market

AbbVie Partnership Expedited Our Global Development

Transformative Collaboration

- Leverage a partner's global clinical, regulatory, medical, patient advocacy and commercial footprint
- **Rights of Parties**

  AbbVie – Worldwide
  (except for PRC, Hong Kong and Macau)

  Jacobio - PRC, Hong Kong and Macau

Financial Arrangement

- **Upfront Payment (Received)**

  $45mm
- **Milestone Payments**

  up to $810mm - $20mm received
- **Royalties**

  Low-to-mid Double-digit percentages
- AbbVie will ***reimburse*** **costs of global clinical development** (incl. China) pre registrational trials

Financial Information

SELECT COMPANY FINANCIALS

(RMB mm)

R&D costs [1]



Financial Position [2]

Cash and Bank Balances @ 12/31/2021	1,538
Cash Runway	18-24 months

[1] *R&D costs = Cost of revenue + Research and development expenses.*
All R&D costs in relation to AbbVie Collaboration were recorded in "Cost of revenue" account.

[2] *As of June 30, 2021, the Group did not have any interest-bearing bank and other borrowing.*

Our Expansion

Global Headquarter
Beijng, China

2021 HC: 262 employees

In-house R&D

Allosteric Inhibitor Tech Platform

Global FIC

6 Clinical Stage Assets (**2** Global TOP 3)

15+ Pipeline Assets (**9** Global TOP 3 Potential)

Global Market

Global Partnership License-out Deals

Full Function Pharma

First NDA in 2023-2024

Beijing Headquarter *(under construction)*

Beijing R&D Center

Beijing Clinical Office (Dazu)

Beijing Clincal office (Shoudong)

Shanghai Clinical Office

U.S. R&D Center in MA

Hebecell R&D Center in MA